Secondary Endpoint Data for S-033188, a Novel Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, Support Favorable Primary Endpoint Data Previously Released

OSAKA, Japan, Dec. 1, 2016 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") presented additional clinical data from a Phase 2 proof-of-concept study for S-033188, a cap-dependent endonuclease inhibitor targeting influenza. The primary endpoint data were previously presented...